20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): AugEndo Internationaįinancial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): SeptemEndo Internatio All rights reserved This presentation containsĮNDO REPORTS THIRD-QUARTER 2021 FINANCIAL RESULTS AND RAISES 2021 FINANCIAL GUIDANCEĮNDO REPORTS SECOND-QUARTER 2021 FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCEĮNDO REPORTS FIRST-QUARTER 2021 FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCEĮndo International plc Announces Pricing of Private Offering Of Senior Secured NotesĮndo International plc Announces Proposed Private Offering Of Senior Secured NotesĮndo International plc Commences Refinancing of its Existing Term Loan Morgan Healthcare Conference Blaise Coleman, President & CEO ©2022 Endo International plc or one of its affiliates. ©2022 Endo International plc or one of its affiliates. Table of Contents 2022A Unaudited Results Feb 2023 Long Term Plan Feb 2023 Segment Projectionsĭisclaimer This document has been prepared by Endo International plc (“Endo” or the “Company”) and its advisors from information provided by Company management and other sources, and is subject in all respects to the confidentiality agreement you havĮndo to Cease Production and Sale of Qwo® (collagenase clostridium histolyticum-aaes)ĮNDO REPORTS THIRD-QUARTER 2022 FINANCIAL RESULTSĮndo International plc (Incorporated in Ireland with limited liability under the Companies Act 2014 with registered number 534814) Notice of Extraordinary General Meeting Convened Pursuant to Section 1111 of the Companies Act 2014Įndo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation Sale Transaction Would Result in a Substantial Reduction of Debt and Contemplates Purchaser-ĮNDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTSĮNDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTSĮndo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From NevakarĮNDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS Most pharmaceutical companies have better annual bonuses and special rewards for their employees compared to this company.THIS DOCUMENT AND THE ACCOMPANYING FORM OF PROXY ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION.ĮNDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTSĮNDO REPORTS FOURTH-QUARTER 2022 FINANCIAL RESULTS Also, people get burned out because they have to give so much of themselves with little return. The workplace culture is not the best, because of a lack of clear communication over the years. I have learned to keep pressing forward to find my niche in the company and have been entrusted with several projects that I was able to work on independently. That's just a part of working in a GMP environment. The fast pace of pharmaceuticals fits my personality and drive although it does become difficult at times to have to be so precise and document each mistake so thoroughly. I have enjoyed my work here, because although a lot of days might seem the same, I have worked with a great group of people. Even though I consistently did outstanding work and did all of the duties of a supervisor, I was not promoted in title which was disappointing. I have been able to flex hours around personal needs and the benefits are great, but the pay could be better. I gave the company an overall 3 stars, because that is average in my opinion.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |